Garivulimab

DB16670InvestigationalProtein Based Therapies

Garivulimab is under investigation in clinical trial NCT03379259 (Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1
Curator reviewed
Code names: BGB-A333

Resolves to

Compound

UNIICSJ7UEQ4D9CAS2342597-81-1

Targets

Q9NZQ7CD274

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Garivulimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account